Development and validation of a LC-FL method for the simultaneous determination of doxorubicin and celecoxib in nanoparticulate fixed dose combination (NanoFDC)

Pharmazie. 2017 Oct 1;72(10):568-570. doi: 10.1691/ph.2017.7077.

Abstract

An isocratic reversed phase HPLC method for the simultaneous determination of doxorubicine (DOX) and celecoxib (CXB) out of a nanoparticulate fixed dose combination (NanoFDC) was developed and validated. Linearity of the results was demonstrated from 1-11 μg/mL for both components. Lower limits of detection were determined as 7 ng/mL for DOX and 13 ng/mL for CXB. Total run time was approximately 15 min.

Publication types

  • Validation Study

MeSH terms

  • Antibiotics, Antineoplastic / analysis*
  • Antineoplastic Combined Chemotherapy Protocols / analysis*
  • Celecoxib / analysis*
  • Chromatography, High Pressure Liquid / methods*
  • Cyclooxygenase 2 Inhibitors / analysis*
  • Doxorubicin / analysis*
  • Drug Combinations
  • Limit of Detection
  • Nanoparticles
  • Reproducibility of Results

Substances

  • Antibiotics, Antineoplastic
  • Cyclooxygenase 2 Inhibitors
  • Drug Combinations
  • Doxorubicin
  • Celecoxib